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ABSTRACT
Neonatal jaundice is caused by high levels of unconjugated bilirubin.
It is usually a temporary condition caused by delayed induction of
UGT1A1, which conjugates bilirubin in the liver. To reduce bilirubin
levels, affected babies are exposed to phototherapy (PT), which
converts toxic bilirubin into water-soluble photoisomers that are
readily excreted out. However, in some cases uncontrolled
hyperbilirubinemia leads to neurotoxicity. To study the mechanisms
of bilirubin-induced neurological damage (BIND) in vivo, we
generated a mouse model lacking the Ugt1a1 protein and,
consequently, mutant mice developed jaundice as early as 36 hours
after birth. The mutation was transferred into two genetic
backgrounds (C57BL/6 and FVB/NJ). We exposed mutant mice to PT
for different periods and analyzed the resulting phenotypes from the
molecular, histological and behavioral points of view. Severity of BIND
was associated with genetic background, with 50% survival of
C57BL/6-Ugt1−/− mutant mice at postnatal day 5 (P5), and of FVB/NJ-
Ugt1−/− mice at P11. Life-long exposure to PT prevented cerebellar
architecture alterations and rescued neuronal damage in FVB/NJ-
Ugt1−/− but not in C57BL/6-Ugt1−/− mice. Survival of FVB/NJ-Ugt1−/−
mice was directly related to the extent of PT treatment. PT treatment
of FVB/NJ-Ugt1−/− mice from P0 to P8 did not prevent bilirubin-
induced reduction in dendritic arborization and spine density of
Purkinje cells. Moreover, PT treatment from P8 to P20 did not rescue
BIND accumulated up to P8. However, PT treatment administered in
the time-window P0-P15 was sufficient to obtain full rescue of
cerebellar damage and motor impairment in FVB/NJ-Ugt1−/− mice.
The possibility to modulate the severity of the phenotype by PT
makes FVB/NJ-Ugt1−/− mice an excellent and versatile model to study
bilirubin neurotoxicity, the role of modifier genes, alternative therapies
and cerebellar development during high bilirubin conditions.
KEY WORDS: Neonatal jaundice, Ugt1, Phototherapy, BIND, Mouse
model
INTRODUCTION
Neonatal jaundice occurs in more than 60% of normal newborns
during their first week of life (Bhutani and Johnson, 2009a; Bhutani
and Johnson, 2009b; Karen et al., 2009) as a result of excessive
unconjugated bilirubin (UCB) formation and transient inability of
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the neonatal liver to clear bilirubin rapidly enough from the blood
owing to delayed expression of UGT1A1, encoding UDP-
glucuronosyltransferase 1a1 (UGT1A1). In fact, the key event in
bilirubin detoxification is the glucuronidation reaction, which is
accomplished by UGT1A1 in the liver (Bosma et al., 1994). Severe
jaundice is also the hallmark of Crigler-Najjar syndrome type I
(CNSI), in which mutations in the UGT1A1 gene result in the
complete and life-long inactivity of the UGT1A1 enzyme.
Modest elevations of plasma UCB in newborns and adults are
considered beneficial owing to the antioxidant properties of bilirubin
(Doré and Snyder, 1999; Doré et al., 1999). The work on Gilbert’s
syndrome increasingly demonstrates the long-term beneficial effects
of low UCB plasma concentrations in averting numerous adult
maladies, including risk for certain cancers and atherosclerosis
(Bulmer et al., 2013; Erlinger et al., 2014; Horsfall et al., 2012;
Novotny and Vítek, 2003; Schwertner and Vítek, 2008; Vítek et al.,
2002). However, severe hyperbilirubinemia is toxic to the
developing central nervous system (Ostrow et al., 2004; Ostrow et
al., 2003). Prolonged and uncontrolled high levels of UCB lead to
bilirubin encephalopathy (BE) and subsequently kernicterus. In
developing countries, up to 35% of newborns with kernicterus die,
and some of the survivors suffer from permanent neurological
sequelae (Kaplan et al., 2011).
Bilirubin targets specific brain regions, such as the basal ganglia,
cochlear, oculomotor nuclei and cerebellum (Lauer and Spector, 2011;
Watchko, 2006b). The spectrum of neurological deficits is severe and
can include movement disorders such as athetoid dystonic cerebral
palsy and oculomotor palsies, sensorineural deafness, auditory
dysfunctions, and dental dysplasia. Despite the severely disabling
cerebral palsy and hearing deficits, most individuals suffering from
bilirubin encephalopathy have normal cognitive capacities. There is
evidence that even moderate neonatal jaundice can result in subtle
neuronal damage, with delayed motor development and minimally
impaired cognitive functions that are unapparent during the neonatal
period but lead to development or neurological impairment that
becomes evident later in life (Chen and Kang, 1995; Oh et al., 2003).
High levels of UCB are conventionally treated by phototherapy
(PT). Light energy (emission range 400-525 nm, peak emission 450-
460 nm) is absorbed by UCB as it circulates in skin capillaries,
resulting in the conversion of insoluble bilirubin into water-soluble
photoisomers that are eliminated into the bile without the need of
liver conjugation (Maisels and McDonagh, 2008). PT is generally
very effective in preventing transient hyperbilirubinemia in healthy
neonates, because the hepatic conjugation system rapidly matures.
However, in some cases high UCB levels concomitant with other
risk factors, such as prematurity, hemolysis, sepsis, dehydration,
early hospital discharge or lack of family training towards jaundice,
can lead to serious neurological outcomes and ultimately death
(Kaplan and Hammerman, 2005; Watchko and Tiribelli, 2013). In
addition, individuals with CNSI, who need lifelong PT treatment for
up to 14 hours per day, respond temporarily to PT and are at
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constant risk of developing brain damage unless liver transplantation
is performed (Fagiuoli et al., 2013).
With the aim of studying the mechanisms of bilirubin toxicity in
vivo, we developed a mouse model bearing a null mutation in the
Ugt1 gene, resulting in early neonatal lethality due to bilirubin
toxicity (Bortolussi et al., 2012). These mutant animals develop
severe jaundice soon after birth and die within 11 days, showing
significant cerebellar alterations and the major features of severe
neonatal jaundice (Bortolussi et al., 2012). We previously showed
that PT treatment of these mutant mice extended their median
survival from 5 to 19 days, but it was not sufficient to rescue their
lethal phenotype (Bortolussi et al., 2012).
In the present work we transferred the Ugt1 genetic mutation into
the FVB/NJ and C57BL/6 mouse strains, and analyzed the
neurodevelopmental effects of bilirubin toxicity in these lethal
murine models of neonatal jaundice. We showed that susceptibility
to bilirubin damage and, consequently, survival of mutant animals
is strain-specific, with a significant increase in the survival of
FVB/NJ-Ugt1−/− compared with C57BL/6-Ugt1−/− mice, the
cerebellum being the most affected organ in both mutant strains.
Cerebellar susceptibility to bilirubin resulted in the alteration of its
architecture, with the important degeneration of Purkinje cell (PC)
dendritic arbor, which was prevented by age-dependent PT
treatment. We identified the critical window of neuronal
susceptibility to bilirubin toxicity and analyzed how high bilirubin
levels affect brain development during the neonatal period. We
showed that FVB/NJ-Ugt1−/− mutant mice were fully rescued when
PT treatment was administered from birth to 15 days of age.
One of the advantages of the presented model resides in the
possibility to modulate phenotype severity by applying PT for
different periods, allowing the study of physiological and
biochemical implications of bilirubin toxicity at the desired
developmental stage.
RESULTS
Phenotype severity is associated with the genetic
background
We have previously reported the generation of a mouse model of
neonatal severe hyperbilirubinemia bearing a targeted mutation in
the Ugt1 gene, which resembles the human CNSI from both the
genetic and phenotypic points of view (Bortolussi et al., 2012). To
reduce variability in the phenotype analysis, a more defined genetic
background was obtained by backcrossing Ugt1 mutant mice for
more than nine generations to wild-type (WT) C57BL/6 mice,
reaching at least 99.8% of C57BL/6 genetic background. Owing to
the lack of Ugt1a1 activity, homozygous mutant mice developed
hyperbilirubinemia within 36 hours after birth, as evident by the
yellow staining of their skin (Fig. 1A), as already reported
(Bortolussi et al., 2012). In this more defined genetic background,
we observed a steeper shape of the mortality curve than found
previously (Bortolussi et al., 2012), with 50% mortality at postnatal
day 5 (P5) (Fig. 1B). To study the effects of Ugt1 deficiency in
another genetic background, we transferred the mutation into the
FVB/NJ strain, reaching at least 99.8% of FVB/NJ genetic
background.
As in the C57BL/6 background, FVB/NJ-Ugt1−/− mice were
visibly jaundiced as early as 36 hours after birth (Fig. 1C).
Interestingly, FVB/NJ-Ugt1−/− mice showed a less severe phenotype
than C57BL/6-Ugt1−/− mice, with 50% survival at 11 days after birth
(P11; Fig. 1B). Prior to death, mutant mice showed features of
bilirubin encephalopathy such as lethargy, dystonia and seizures
(supplementary material Movie 1).
Determination of plasma total bilirubin (TB) showed that levels
in C57BL/6-Ugt1−/− mice were significantly higher than in FVB/NJ-
Ugt1−/− mice at both time points analyzed (Fig. 1D; two-way
ANOVA, interaction time-genotype, NS; time, P≤0.05, genotype,
P≤0.0005; Bonferroni’s post-hoc comparison test: P≤0.05 and
P≤0.01 C57BL/6-Ugt1−/− versus FVB/NJ-Ugt1−/−, at P2 and P5,
respectively). Moreover, we observed that total plasma bilirubin of
FVB/NJ-Ugt1−/− mice significantly increased with time, reaching
plasma bilirubin levels of C57BL/6-Ugt1−/− levels in later time
points (Fig. 1E; two-way ANOVA, interaction time-genotype,
P≤0.0001; time, P≤0.0001, genotype, P≤0.0001; see also
supplementary material Table S1).
To exclude the possibility that the differences in plasma TB and
mortality could be associated with increased lysis of red blood cells
in the C57BL/6 strain, we determined the erythrocyte osmotic
fragility from both strains in WT P5 pups and adults. The neonatal
period is known to have a high level of erythrocyte hemolysis
(Pearson, 1967), but our data show that there were no differences
between the strains in the NaCl concentration required for 50%
hemolysis (C50), both in pups and adults (Fig. 1F,G, respectively).
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TRANSLATIONAL IMPACT
Clinical issue
Neonatal jaundice is caused by high serum levels of unconjugated
bilirubin, a yellow pigment that is the breakdown product of hemoglobin.
It is more common and severe in preterm than in term babies, and is
usually a temporary condition caused by delayed induction of UDP-
glucuronosyltransferase 1a1 (Ugt1a1), which conjugates bilirubin for
excretion. The condition can be treated with phototherapy, which
converts bilirubin into a water-soluble form. Left untreated, severe
neonatal hyperbilirubinemia, which is also the hallmark of Crigler-Najjar
syndrome type I (a genetic disorder caused by mutations in the UGT1A1
gene), can damage the nervous system, leading first to bilirubin
encephalopathy and then to kernicterus (‘yellow’ staining of the brain
tissue due to accumulation of bilirubin). About 70% of newborns who
develop kernicterus die within a few days and survivors often have
permanent neurological deficits. However, the extent of neurological
damage caused by similar levels of unconjugated bilirubin varies widely,
which makes it hard to assess the risk threshold of hyperbilirubinemia
or to develop intervention guidelines. 
Results
The mechanism of bilirubin neurotoxicity remains poorly understood
because of the limitations of existing cellular and animal models. In this
study, the authors developed a mouse model bearing a null mutation in
the Ugt1 gene that results in early neonatal lethality due to
hyperbilirubinemia. They investigated bilirubin neurotoxicity in two
genetic backgrounds and showed that susceptibility to bilirubin damage
and the survival of mutant animals is strain-specific, a result that
underscores the importance of modifier genes in the modulation of
bilirubin toxicity. Using phototherapy at different times after birth, the
authors identified the critical window of neuronal susceptibility to bilirubin
toxicity and showed that the neurotoxic effects of bilirubin depend on the
developmental stage of the cerebellum. Finally, they reported that
phototherapy from birth to day 15 is sufficient to rescue mutant mice from
cerebellar damage and motor impairment. 
Implications and future directions
The results obtained in the mouse model developed here closely mirror
the effects of hyperbilirubinemia in preterm infants. Thus, this new model
will help the characterization of the molecular mechanisms of bilirubin
toxicity during this critical period of human development. Moreover, the
ability to modulate the phenotype severity by applying phototherapy for
different periods makes this model a valuable and versatile setting in
which to study bilirubin toxicity at different developmental stages, the

















Bilirubin induces neurological damage in the cerebellum of
FVB/NJ-Ugt1−/− mutant mice
We exposed newborn mutant pups to blue light (λ=450 nm, 12
hour/day) from birth. Life-long PT treatment resulted in survival of
all FVB/NJ-Ugt1−/− mice, whereas all C57BL/6-Ugt1−/− pups died
within day 20 after birth (Fig. 1H). Because we have previously
reported that bilirubin causes severe cerebellar abnormalities and
death of C57BL/6-Ugt1−/− mice, we analyzed brain morphology at
P8 in untreated or PT-treated mutant mice and in WT littermates in
FVB/NJ genetic background. We observed that untreated mutant
cerebella showed important modifications of the architecture of the
cerebellar fissures (Fig. 2A), in the depth of the cerebellar layers
(Fig. 2B) and in the arborization of PCs (Fig. 2C). In contrast to
what was observed in the C57BL/6-Ugt1−/− strain, in which we
reported a 37% reduction in PC number, we did not observe a
significant decrease in PC density in cerebella of P8 FVB/NJ-
Ugt1−/− mice (Fig. 2C). We then performed a western blot analysis
of cerebellar extracts using anti-calbindin antibody, a calcium-
binding protein exclusively expressed by PCs in the cerebellum
(Whitney et al., 2008), as a marker of PC impairment. Densitometric
quantification of the bands revealed that untreated FVB/NJ-Ugt1−/−
mutant mice had a 50% reduction of calbindin content in their
cerebella compared with WT littermates (Fig. 2D), confirming the
observation of an important reduction in PC dendritic arbor. In
addition, we performed terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick-end labeling (TUNEL)
analysis of entire brain sections and observed an increase of
TUNEL-positive cells in the cerebellum of untreated mutant mice
(Fig. 2E). TUNEL-positive cells were not restricted to a specific
layer of the cerebellum: they were present in the external germinal
layer (EGL), Purkinje cell layer (PCL) and in the internal granular
layer (IGL). We analyzed other areas of the brain (cortex,
hippocampus, basal ganglia), but we did not observe differences in
their architecture, or an increase of TUNEL-positive cells, compared
with WT littermates (data not shown).
PT treatment from birth fully rescued all features of bilirubin
neurotoxicity (Fig. 2A-E).
Bilirubin affects dendritic arborization and spine density of
PCs in vivo
Next, we exposed FVB/NJ-Ugt1−/− mice and their WT littermates to
PT for different periods, starting at birth (P0), up to P8, P10 and
P15. At the indicated time points mice were removed from PT and
kept under normal light (Fig. 3A). As expected, survival of mutant
mice was directly related to the extent of PT treatment (Fig. 3B).
Discontinuation of PT treatment resulted in a rapid increase of
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Fig. 1. Comparison between C57BL/6-Ugt1−/− and FVB/NJ-Ugt1−/− mice. (A) Appearance of a C57BL/6-Ugt1−/− mouse (red arrowhead) and its WT littermate
at P2. (B) Kaplan-Meier survival curves of C57BL/6-Ugt1−/− (black line with ■, n=12) and FVB/NJ-Ugt1−/− mice (dashed black line with ●, n=21) under normal
light conditions (P≤0.001). (C) Appearance of an FVB/NJ-Ugt1−/− mouse (red arrowhead) and its WT littermate at P2. (D) Total plasma bilirubin levels in
C57BL/6-Ugt1−/− and FVB/NJ-Ugt1−/− mice. Values represent means±s.d. (mg/dl). Two-way ANOVA, *P≤0.05 and **P≤0.01, C57BL/6-Ugt1−/− versus FVB/NJ-
Ugt1−/− at P2 and P5, respectively. (E) Time course of total plasma bilirubin levels in FVB/NJ Ugt1+/+ (WT) and FVB/NJ Ugt1−/− (MUT) mice. Two-way ANOVA.
Interaction time-genotype, P≤0.0001; time, P≤0.0001, genotype, P≤0.0001. Values represent means±s.d. (mg/dl). (F) Osmotic fragility (OF) test of erythrocytes
from P5 WT C57BL/6 and FVB/NJ animals. (G) OF test of erythrocytes from adult WT C57BL/6 and FVB/NJ animals. Results are expressed as percentage of
lysis in graded salt concentrations (mean±s.d. of five males and five females). C50 values were determined by logarithmic linearization of the OF curve.

















bilirubin levels, reaching a plateau value of 14-16 mg/dl 3 days after
PT removal (Fig. 3C,D), whereas, during PT treatment, mutant mice
had TB levels of 3.9±0.4 mg/dl (Fig. 3D), well below those
conferring the risk of developing neurological damage (Bortolussi
et al., 2012). We analyzed cerebellar morphology at P15 and did not
observe significant alterations of cerebellar fissures after the
different treatments (Fig. 3E). Moreover, at this stage, cerebellar
layer thickness was comparable among all treatments and was not
statistically different from WT littermates (Fig. 3F). In addition, the
PC number and calbindin content (quantified by densitometric
analysis of the western blot bands) was comparable among all
treatments and was not statistically different from WT littermates
(Fig. 3G and supplementary material Fig. S1). These results
indicated that PT treatment for 8 days after birth was sufficient to
avoid major cerebellar abnormalities. However, calbindin staining
of cerebella showed an apparent impairment of the PC dendritic
arbor in P0-P8 PT-treated mutant mice, when determined at P15
(Fig. 3G).
Owing to the high density and complexity of dendritic arbors in
the PC layer, it was not possible to quantify the extent of PC
impairment directly in anti-calbindin-immunostained sections.
Thus, we assessed morphological changes in individual PCs by
Golgi staining in P0-P8 PT-treated mutant mice at P15 and
compared them with WT littermates (Fig. 4). Golgi staining is a
very powerful technique that allows the analysis of morphological
features such as dendritic arborization and spines of individual
neurons in the brain (Ranjan and Mallick, 2010). After Golgi
staining, ten single PCs with a complete dendritic arbor were
selected from each animal (four animals/genotype). We
reconstructed the dendritic arbor of each PC and measured three
parameters: total dendritic length, number of branching points and
average length of each branch. The total length of the PC dendritic
arbor and the number of branching points from P0-P8 PT-treated
mutant mice were reduced 16% and 17%, respectively, compared
with WT littermates (Fig. 4A,B). In contrast, the average length of
each branch (calculated as the ratio between total dendritic length
and the number of branching points) was not reduced by bilirubin
(Fig. 4C), suggesting that the entire dendritic arbor of PCs in P0-
P8 PT-treated mutant mice was shorter in length owing to a
reduction in the branching number, maintaining the same distance
between successive branches. To more accurately assess subtle
damage produced by bilirubin in P0-P8 PT-treated mutant mice,
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Fig. 2. Characterization of P8 cerebellar
lesions in FVB/NJ-Ugt1−/− mice with and
without PT treatment. (A) Nissl staining of 
8-day-old (P8) WT, untreated mutant and PT-
treated mutant mice. Boxed areas indicate
fields shown in panel B. IV, VIa, VIb and IXb
indicate the cerebellar fissures. Scale bar:
200 μm. (B) High-magnification images of
cerebellar layers from P8 mice and, in the right
panel, layer depth quantification (four
mice/genotype). EGL, external germinal layer;
PCL, Purkinje cell layer; IGL, internal granular
layer. Scale bar: 100 μm. Error bars, s.d.
(C) Representative fluorescent
immunohistochemistry and quantification of PC
number (cells/mm) from P8 WT, untreated
mutant and PT-treated mutant mice. PCs were
stained with anti-calbindin1 antibody (green)
and nuclei with Hoechst staining (blue). Scale
bar: 50 μm. Quantification of the PC number
(cells/mm) is represented in the right panel
(four mice/genotype). Error bars, s.d. One-way
ANOVA test not significant. (D) Western blot
analysis of total cerebellum protein extract
using an anti-calbindin1 antibody in P8 WT,
untreated mutant and PT-treated mutant mice.
Tubulin was used as a loading control. Lower
panel: densitometric quantification of the
bands. (E) TUNEL analysis. Positive cells are
shown as brown dots; negative cells are
counterstained with methyl green. Scale bar:

















we performed the Sholl analysis of PCs, a quantitative method for
morphometric neuronal studies (Sholl, 1953). Sholl analysis
revealed that PCs from P0-P8 PT-treated mutant mice had a
reduced dendritic complexity compared with WT controls. The
reduction was particularly evident at a distance between 70 to
110 μm from the soma (Fig. 4D).
Moreover, to deeply characterize subtle bilirubin-induced
damage, we measured spine density in PCs of P0-P8 PT-treated
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Fig. 3. Efficacy of PT treatment in FVB/NJ-Ugt1−/− mice. (A) Schematic representation of PT treatment. FVB/NJ-Ugt1−/− mice and their WT littermates were
exposed to PT (blue arrows) for different periods, starting at birth (P0) up to P8, P10, P12 and P15. At the indicated time points, mice were removed from PT
and kept under normal light (yellow arrows). (B) Kaplan-Meier survival curves of FVB/NJ-Ugt1−/− mice under normal light conditions (red line with ●, n=21),
treated with PT for 8 days (light blue line with ▲, n=13), 10 days (blue line with ■, n=10) and 15 days (dark blue line with , n=11) (P≤0.001). (C) Total plasma
bilirubin (TB) levels at P15 of P0-P8, P0-P10, P0-P12 and P0-P15 PT-treated FVB/NJ-Ugt1−/− mutant mice (n=14, 5, 4 and 6, respectively) and WT littermates
(n=9). One-way ANOVA test with Bonferroni’s post-hoc comparison tests; ns, not significant; *P≤0.05, ***P≤0.001. (D) Total plasma bilirubin levels in WT and
FVB/NJ-Ugt1−/− mice. Values represent means±s.d. Values in parenthesis indicate number of samples analyzed. (E) Nissl staining of 15-day-old (P15) WT and
PT-treated mutant mice. Boxed areas indicate fields shown in panel F. (F) High-magnification images of cerebellar layers from P15 mice and, in the right panel,
layer depth quantification (four mice/treatment group). Scale bar: 100 μm. Error bars, s.d. One-way ANOVA test not significant. (G) Representative fluorescent
immunohistochemistry and quantification of PC number (cells/mm) from P15 WT and PT-treated mutant mice. PCs were stained with anti-calbindin1 antibody
(green) and nuclei with Hoechst staining (blue). Scale bar: 50 μm. Quantification of the PC number (cells/mm) is represented in the right panel (four

















mutant mice and WT littermates. We observed that mutant mice
had about 16% less spines/μm compared with healthy control
animals (Fig. 4E,F).
In summary, these results show that the degree of bilirubin-
dependent cerebellar neurodegeneration in vivo depends on the
developmental stage of the specific cell type. Earlier bilirubin
toxicity (P0-P8), as in untreated mutant animals, affects the granule
cells (GCs) of the EGL and PCs, leading to decreased thickness of
both the EGL and PCL, plus the almost total disruption of PC
dendritic arbor. In contrast, later exposure (from P8 on) to high
bilirubin levels affects only PC dendritic arborization and spine
density. PCs receive impulses from several regions of the CNS, such
as spinal cord, vestibular nucleus and cerebral cortex. Because their
axons are the only synaptic output of the cerebellum, damage to
these cells will deeply affect cerebellar functions.
Phototherapy does not retrieve bilirubin-induced
neurological damage accumulated up to P8
Because P8 seemed to be a key time point for bilirubin toxicity in
the cerebellum of our FVB/NJ-Ugt1−/− mice, next, we investigated
whether the damage produced by bilirubin was reversible. Thus,
mutant mice were left untreated up to P8, were then exposed to PT
from P8 to P20 and their survival was monitored (Fig. 5A).
Interestingly, we observed that we were able to rescue about 27% of
mice receiving P8-P20 PT treatment (about 20% of mutant animals
analyzed died before initiating the PT treatment and were not
included in this calculation), whereas only 7% of the mutant animals
treated from P0 to P8 with PT survived (Fig. 5B).
Survivors from P8-P20 PT treatment were tested for their motor
coordination abilities on the accelerated rotating rod. The analysis
was performed at 1 and 2 months of age (Fig. 5C). We observed that
surviving mutant mice were severely impaired in their motor
coordination performance compared with their WT littermates and
that the difference was more evident at 2 months of age compared
with 1 month (two-way ANOVA repeated measurements,
Bonferroni’s post-hoc comparison test, 1 month P>0.05; 2 months
P≤0.05, WT versus MUT P8-P20 PT).
We quantified TB levels at P15 and observed that PT treatment
was very efficient in dropping down bilirubin levels from
16.6±3.1 mg/dl (TB levels of P0-P8 PT-treated mutant mice) to
2.1 mg/dl (Fig. 3D and Fig. 5D).
Histological analysis of the cerebellum of P8-P20 mutant 
mice highlighted an important cerebellar hypoplasia at P15. In
fact, the molecular layer (ML) and IGL thickness was reduced
about 73% and 54%, respectively, compared with WT littermates
(Fig. 5E). We have described above that bilirubin decreases 
EGL and PCL thickness in untreated animals, but not IGL
thickness, at P8 (Fig. 2B). We can speculate that the reduction 
seen in P8-P20 PT-treated mutant mice at P15 is the result of two
main events: a stall in the duplication of GCs in the EGL, and cell
death in all the layers of the cerebellum (see TUNEL analysis,
Fig. 2E).
Interestingly, at the time when mutant animals were exposed to
PT (at P8), they had high TB levels (12.5±0.9 mg/dl; Fig. 1E and
supplementary material Table S1) and did not show an important
reduction in PC number (Fig. 2C). However, after receiving 7 days
of PT they showed low TB levels (Fig. 3D; PT P8-P20 group) but a
62% decrease in PC number (Fig. 5F), suggesting that exposure of
PCs to bilirubin from P0 to P8 triggered substantial cell death events
(see TUNEL analysis, Fig. 2E) that were not prevented by the
successive PT treatment.
PT treatment was discontinued at P20 and 10 days later the
cerebella of the mutant mice and their WT littermates were
analyzed. ML and IGL thickness was still significantly reduced
compared with WT littermates, although this difference was less
pronounced than at P15 (by 32% and 24%, respectively; Fig. 5G).
We speculate that the reduction of TB levels during P8-P20 allowed
the spared GCs of the EGL to duplicate and recover part of the
cerebellar architecture. The number of PCs decreased further; in fact
there were 52% less compared with WT littermates (Fig. 5H).
Thanks to PT treatment, the differences in layer thickness was
reduced and spared PCs slightly improved their dendritic arbor
compared with P8-P20 mutant animals analyzed at P15 (compare
Fig. 5E,F to 5G,H).
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Fig. 4. Bilirubin reduces dendrite complexity
and spine density of PCs. Comparison of PCs
from WT and P0-P8 PT-treated FVB/NJ-Ugt1−/−
mice at P15 (four mice/genotype). (A) Total
dendritic length (μm). t-test analysis. *P≤0.05.
(B) Number of branches. t-test analysis. *P≤0.05.
(C) Average dendritic length (μm). t-test, not
significant. (D) Sholl-analysis-derived distribution
of PCs and mean number of intersections of
dendrite branches. t-test analysis. *P≤0.05;
**P≤0.01. (E,F) Spine density (%) and
representative pictures of PC spines in WT and
P0-P8 PT-treated mutant mice at P15. Mann-
















PT treatment for only 15 days is sufficient to fully rescue
survival, and histological and behavioral features of FVB/
NJ-Ugt1−/− mice
When mutant mice were exposed to PT from P0 to P15, we
observed 100% survival of treated mice (Fig. 3B). To determine
whether 15 days of PT was sufficient to fully rescue mutant mice,
we performed a more detailed histological, functional and molecular
analysis. We observed that continuous PT treatment of mutant mice
for 15 days prevented all morphological and functional deficits
produced by bilirubin neurotoxicity, such as alterations in cerebellar
morphology (Fig. 6A), and differences in layer thickness (Fig. 6B)
and in the number and arborization of PCs (Fig. 6C). In addition, we
observed that P0-P15 PT-treated mutant mice did not show any
obvious motor coordination impairment as assessed by the
accelerating rotarod test at any of the time points analyzed (Fig. 6D).
DISCUSSION
Neonatal hyperbilirubinemia is the most common cause of hospital
readmission in the first week of life (75%) (Escobar et al., 2005).
There is a growing concern in the pediatric field regarding
bilirubin neurotoxicity during the neonatal period because high
bilirubin levels are life threatening and if neglected can lead to
permanent brain disabilities and ultimately death. Moreover,
infants show a huge variability in the extent of neurological
damage caused by similar UCB levels, limiting the capacity to
assess risk threshold for neurotoxicity and common intervention
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Fig. 5. Characterization of P15 cerebellar lesions in P8-P20 PT-treated FVB/NJ-Ugt1−/− mice. (A) Schematic representation of PT (blue arrows) treatment.
(B) Kaplan-Meier survival curves of FVB/NJ-Ugt1−/− mice treated with PT from P0 to P8 (light blue line with ●, n=13) and from P8 to P20 (dark blue line with ■,
n=18). (C) Time course of motor coordination performance on rotarod of WT and P8-P20 PT-treated mutant mice (n=4/genotype). Two-way ANOVA test,
interaction time-genotype, not significant (NS); time, NS; genotype, P≤0.01; Bonferroni’s post-hoc comparison tests: NS and P≤0.05 WT versus FVB/NJ-
Ugt1−/−, at 1 and 2 months, respectively). *P≤0.01. WT, Ugt1 wild-type allele; MUT, Ugt1 mutant allele. (D) Total plasma bilirubin levels of P0-P8 and P8-P20
PT-treated mutant mice at P15 (n=14 and 4, respectively). t-test analysis. ***P≤0.0001. (E) High-magnification images of cerebellar layers from P15 mice and,
in the right panel, layer depth quantification (four mice/genotype). ML, molecular layer; IGL, internal granular layer. Scale bar: 100 μm. Error bars=s.d. t-test
analysis. ***P≤0.0001. (F) Representative fluorescent immunohistochemistry and quantification of PC number (cells/mm) from P15 mice. PCs were stained
with anti-calbindin1 antibody (green) and nuclei with Hoechst staining (blue). Scale bar: 50 μm. Quantification of the PCs number (cells/mm) is represented in
the right panel (four mice/genotype). Error bars=s.d. t-test analysis. ***P≤0.0001. (G) High-magnification images of cerebellar layers from P30 mice and, in the
right panel, layer depth quantification (four mice/genotype). Scale bar: 100 μm. Error bars=s.d. t-test analysis. **P≤0.001. (H) Representative fluorescent
immunohistochemistry and quantification of PC number (cells/mm) from P30 mice. PCs were stained with anti-calbindin1 antibody (green) and nuclei with


















guidelines (Shapiro, 2003; Watchko and Jeffrey Maisels, 2010;
Wennberg et al., 2006). During the past decades numerous
progresses in understanding the mechanism by which bilirubin
causes neurological damage have been made (Watchko and
Tiribelli, 2013). However, the molecular and cellular mechanisms
of bilirubin toxicity are still poorly defined owing to limitations of
the available animal and cellular models.
To study bilirubin toxicity in vivo, we generated a mutant mouse
model of neonatal hyperbilirubinemia lacking Ugt1a1 enzyme
activity (Bortolussi et al., 2012). Mutant mice develop severe
hyperbilirubinemia as early as 36 hours after birth, severe
neurological damage and early lethality, recapitulating all major
features of severe neonatal jaundice and bilirubin-induced
neurological damage (BIND).
Strain-specific bilirubin susceptibility
We characterized the lethal effects of Ugt1 deficiency in two mouse
genetic backgrounds, C57BL/6 and FVB/NJ, showing important
differences in phenotype severity between the strains. In fact, mutant
pups in the C57BL/6 genetic background had a median survival of 5
days (Bortolussi et al., 2012), whereas those in the FVB/NJ genetic
background survived longer, with a median survival of 11 days. The
differences in severity between the strains seem to be associated with
the increased plasma bilirubin values in the C57BL/6 mice but not to
a difference in erythrocyte fragility. We have shown that this
difference is not associated with increased hemolysis and bilirubin
production in the C57BL/6 strain, despite this strain having higher red
cell count (10.3×106 versus 9.2×106, for C57BL/6 and FVB/NJ,
respectively; http://phenome.jax.org) and hematocrit values (50.2 and
43.4, for C57BL/6 and FVB/NJ, respectively; http://phenome.jax.org).
Other genetically engineered mouse models, such as EGF
receptor, retinoblastoma-related p130, fibronectin and Tgfb1
knockout (KO) strains, also showed that differences in the genetic
background cause considerable variations in the phenotype
(Doetschman, 2009; George et al., 1997; LeCouter et al., 1998a;
LeCouter et al., 1998b; Threadgill et al., 1995). These important
differences in phenotype severity are not yet fully elucidated, but
seem to be associated with the modulatory effects of modifier genes
(Astrof et al., 2007; Doetschman, 2009). Here, we have shown that
the less severe phenotype of FVB/NJ-Ugt1−/− mice correlates with
the reduced cerebellar morphological defects, as compared with
C57BL/6-Ugt1−/− mice. In fact, C57BL/6 mutant mice showed a
significant reduction both in the number of PCs and depth of
cerebellar layers, whereas the number of PCs in FVB/NJ-Ugt1−/−
mice was not affected and the differences in cerebellar layers were
less pronounced. A more detailed analysis showed that, in the FVB
model, PC dendritic arborization is affected, similarly to that
observed in C57BL/6-Ugt1−/− pups (Bortolussi et al., 2012).
Interestingly, the mouse models characterized in this study have
the same genetic mutation present in the hyperbilirubinemic Gunn
rat (Bortolussi et al., 2012; Iyanagi et al., 1989), but displayed a
much stronger phenotype. In fact, all mutant mice died a few days
after birth due to bilirubin toxicity. Over time, different colonies of
Gunn rats were used to study bilirubin toxicity, with phenotypes
ranging from complete survival of untreated animals, with cerebellar
abnormalities and hearing impairment, but reaching adulthood and
reproducing (Chowdhury et al., 1993), to partial lethality (Keino and
Kashiwamata, 1989; Keino et al., 1985-1986). Early studies in the
Gunn rats (Johnson et al., 1959) reported plasma bilirubin levels
similar to those found in the FVB/NJ-Ugt1−/− mouse strain, although
mortality was low and difficult to interpret owing to intercurrent
infections. A more severe phenotype of the Gunn rats was obtained
by treatment, at different postnatal days, with sulfadimetoxine,
showing histological abnormalities in the cerebellar layers and PCs
(Conlee and Shapiro, 1997; Schutta and Johnson, 1967; Schutta and
Johnson, 1969; Schutta and Johnson, 1971) similar to those
observed in our untreated mutant mouse strains. Other important
differences are also observed when Ugt1 mutant mice and the Gunn
rats are exposed to PT: a single 24-hour dose of PT is enough to
rescue Gunn rat lethality and prevent hypoplasia in the cerebellum,
with treatment at day 7 being most effective (Keino and
Kashiwamata, 1989) and the critical period for bilirubin-induced
cerebellar hypoplasia being between P6 and P10 (Conlee and
Shapiro, 1997; Keino and Kashiwamata, 1989; Sawasaki et al.,
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Fig. 6. Characterization of P30 cerebellar lesions in FVB/NJ-Ugt1−/− mice exposed for 15 days to PT. (A) Nissl staining of 30-day-old WT and P0-P15 PT-
treated mutant mice. Boxed areas indicate fields shown in B. (B) High-magnification images of cerebellar layers from P30 mice and, in the right panel, layer
depth quantification (four mice/genotype). Scale bar: 100 μm. Error bars, s.d. t-test analysis, not significant. ML, molecular layer; IGL, internal granular layer.
(C) Representative fluorescent immunohistochemistry and quantification of PC number (cells/mm) from P15 mice. PCs were stained with anti-calbindin1
antibody (green) and nuclei with Hoechst staining (blue). Scale bar: 50 μm. Quantification of the PC number (cells/mm) is represented in the right panel (four
mice/genotype). Error bars, s.d. t-test analysis, not significant. (D) Time course of motor coordination performance on rotarod of WT and P0-P15 PT-treated
















1976). In contrast, continuous PT is required in FVB/NJ-Ugt1−/−
mice to rescue lethality, whereas this treatment is not sufficient to
prevent death of C57BL/6 mutant animals.
Modulation of phenotype severity
We have presented here a novel and versatile model to study
bilirubin toxicity. One of the advantages resides in the possibility to
modulate phenotype severity by applying PT for different periods,
allowing the study of physiological and biochemical implications of
bilirubin toxicity at the desired developmental stage. For example,
we studied the effects of bilirubin toxicity in mutant FVB/NJ-
Ugt1−/− mice treated with PT for 8 days. In these mice, despite the
absence of gross cerebellar abnormalities, and a similar number of
PCs and calbindin levels compared with WT mice, almost 90% of
mutant mice did not survive. A more detailed analysis showed a
significant reduction in dendritic arborization and in spine density,
suggesting that these defects could contribute to neuronal
abnormalities and death. When we extended PT treatment for
another 2 days (P0-P10 PT), we observed a less severe condition,
which resulted in about 50% survival.
We anticipate that these experimental conditions are valuable
when the effect of a specific gene under study or pharmacological
treatment is masked by the severity of hyperbilirubinemia, a
condition that underestimates the therapeutic outcome or molecular
partner contribution. Again, the readout of the experiment will be as
simple as the increase of the survival rate.
The window of neuronal susceptibility
It is known that the cerebellum is particularly vulnerable to insults
because of its very rapid growth during peri- and postnatal
development (Biran et al., 2012; Fonnum and Lock, 2000). Upon
accomplishment of the early cerebellar patterning in which two
germinal compartments (dorsal rhombic lip and the ventricular zone
of the fourth ventricle) are generated, the cerebellar development
experiences two main phases: (1) migration and proliferation of
rhombotic lip progenitors to populate the external germinal layer;
and (2) migration and differentiation of the PCs to populate the PCL
(Roussel and Hatten, 2011).
Shortly after birth, GC progenitors undergo a strong and
prolonged phase of clonal expansion in the EGL that lasts up to
P20. The proliferation and migration of GCs is regulated by PC
growth factors. After several cycles of duplication, GCs located in
the external part of the EGL (facing the PCL) stop duplicating and
migrate radially inward to their final destination in the IGL.
During their migration into the IGL, GCs extend their T-shaped
axons orthogonal to their migration path to generate the parallel
fibers. Once in the IGL they will end their maturation process and
receive input from the mossy fibers of the cortico-pontocerebellar
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Fig. 7. Model of bilirubin toxicity during postnatal cerebellar development in the FVB/NJ-Ugt1−/− mouse model. Bilirubin toxicity during the neonatal
period produces different outcomes depending on the developmental period of exposure. The window of high toxicity is between P0 and P8. The main events
occurring in the cerebellum during this period are granule cell (GC) proliferation and migration, and Purkinje cells (PCs) extend their dendritic arbor. Bilirubin
causes early neonatal lethality and substantial cerebellar damage. Later exposures (after P8) increase the number of spared animals and produce subtle
damages, such as reduction of PC dendritic arbor and spine density. After P15, bilirubin does not cause lethality and evident cerebellar abnormalities. The
comparison with human cerebellar development revealed that the critical window of toxicity is between the 24th and 38th gestational week (gw), also referred 
as the very preterm and preterm period, respectively. It is known that very preterm and preterm infants have a higher risk of developing bilirubin-induced
















neurons, the main input of the cerebellum. Concomitant with the
onset of GC parallel fibers, PCs differentiate by completing their
dendritogenesis.
Rodents and humans share a high degree of conservation of
cerebellar anatomy and function, although the timing is slightly
different (Biran et al., 2012). As described above, in rodents the
proliferation of the EGL and the formation of the IGL occur
postnatally, whereas the same phase in humans occurs between the
24th gestational week and birth (Fig. 7). Similarly, the main part of
PC differentiation happens prenatally in humans, but postnatally in
rodents. Thus, it is not surprising to note that cerebellar
abnormalities in babies are a common complication of very
premature and premature births (24-28 and 28-32 gestational weeks,
respectively). Survivors frequently show a broad range of disabilities
connected to cerebellar development, such as hypotonia, fine motor
coordination failures, ataxia, impaired motor coordination
sequencing and cerebral palsy (Haldipur et al., 2011; Limperopoulos
et al., 2005; Volpe, 2009).
Preterm gestation is one of the most prevalent known risk factors
for the development of severe hyperbilirubinemia and kernicterus
(for a detailed review, see Watchko, 2006b); in fact,
hyperbilirubinemia in preterm infants is more frequent and severe
and its course is more prolonged then in term infants (Bhutani and
Johnson, 2006). Treatment guidelines indicate that infants at higher
risk to develop bilirubin-induced neurological sequelae are those
born between the 35th and 37th gestational weeks (Watchko,
2006a). The spectrum of bilirubin-induced neurological disabilities
also include movement disorders such as dystonia, athetosis,
cerebral palsy and occasionally spasticity, which are well-known
markers of basal ganglia, cerebellum and brainstem damage
(Shapiro et al., 2006).
The results obtained in our mouse model mirror what has been
reported so far in preterm and term infants. In fact, exposure of
mutant mice to high levels of bilirubin during the first 8 days after
birth (corresponding to preterm period in humans) causes severe
neurological damage and a high mortality rate; at later time points
(after P8, corresponding to term and late term infants), we reported
a gradual decrease in the mortality rate, accompanied by less severe
neurological outcomes (Fig. 7). It is well known that bilirubin
neurotoxic effects can still be reversible if bilirubin levels are
promptly reduced, avoiding permanent damage (Hansen et al., 2009;
Zuccoli et al., 2011), although a range of outcomes suggests inter-
individual variations in vulnerability (Hankø et al., 2001). In
patients, the likelihood of reversing advanced stages depends on the
implementation of rapid and effective treatments, such as intensive
PT (Hansen, 2011) and exchange transfusion (Keenan et al., 1985;
Roussel and Hatten, 2011).
In our FVB/NJ-Ugt1−/− mice, the reversibility threshold seems to
be before P8: when PT was applied from P8 and mutant mice
analyzed at P15 (Fig. 5), a compromised motor-coordination
function was observed, together with reduced depth of cerebellar
layers, PC number and dendritic arborization. These damages were
not reversed in spite of low plasma bilirubin values from P8 to P20
as the result of PT treatment. Such a critical period suggests that, 
in preterm infants, the identification and treatment of
hyperbilirubinemia must be prompt and very efficient.
To summarize, we have shown here the consequences of the Ugt1
null mutation in two mouse genetic backgrounds, with C57BL/6-
Ugt1−/− mice showing a more severe phenotype than FVB/NJ-
Ugt1−/− ones. We showed that PT treatment was effective in the
prevention of brain damage and resulted in the complete rescue of
the lethal phenotype only in the FVB/NJ-Ugt1−/− animals. It emerges
that susceptibility to bilirubin damage and, consequently, survival of
mutant animals seems to be strain- and species-specific,
underscoring the importance of modifier genes in the modulation of
bilirubin toxicity.
The better characterization of the molecular mechanisms of
bilirubin toxicity in the two mouse strains could result in the
identification of novel genes involved in the modulation of bilirubin-
induced neurological damage. Moreover, the capability to
manipulate the mouse genome will allow the generation of mouse
models of genes potentially involved in bilirubin metabolism that
are expected to improve the comprehension of the mechanisms of
UCB toxicity and protection. In view of these observations,
FVB/NJ-Ugt1−/− mice represent an excellent and versatile model to
study bilirubin toxicity, the role of modifier genes and the
effectiveness of new therapeutic approaches.
MATERIALS AND METHODS
Animals
Ugt1 mutant mice in the C57BL/6 background have been generated
previously (Bortolussi et al., 2012). WT littermates were used as a control.
Mice were housed and handled according to institutional guidelines, and
experimental procedures approved by the International Centre for Genetic
Engineering and Biotechnology (ICGEB) board, with full respect to the EU
Directive 2010/63/EU for animal experimentation. Animals used in this
study were at least 99.8% C57BL/6 or FVB/NJ genetic background,
obtained after more than nine backcrosses with C57BL/6 and FVB/NJ mice,
respectively. Mice were kept in a temperature-controlled environment with
12/12 hours light/dark cycle. They received a standard chow diet and water
ad libitum.
Phototherapy treatment
Newborns were exposed to blue fluorescent light (20 μW/cm2/nm, Philips
TL 20W/52 lamps; Philips, Amsterdam, The Netherlands) for 12 hours/day
(synchronized with the light period of the light/dark cycle) up to the
indicated postnatal day and then maintained under normal light conditions.
Intensity of the blue lamps was monitored monthly with an Olympic Mark
II Bili-Meter (Olympic Medical, Port Angeles, WA). The distance from the
lamps to the bottom of the cases was ~27 cm.
Bilirubin measurements
Blood samples were collected at different time points in mutant and WT
littermates by decapitation or cardiac puncture in EDTA-collecting tubes.
Total bilirubin (TB) determination in plasma was performed using Direct
and Total Bilirubin Reagent kit (BQ Kits, San Diego, CA) adapting the
method to use minimal volumes (10 μl of plasma). The adaptation of the
method consisted in the reduction of the volumes (all), in order to use less
sample volume. The original proportions were maintained. Three
commercial bilirubin reference standards (Control Serum I, Control Serum
II and Bilirubin Calibrator, Diazyme Laboratories, Poway, CA) were
included in each set of analysis as quality control. Absorbance values at 560
nm were obtained by using a multiplate reader (Perkin Elmer Envision Plate
Reader, Walthman, MA).
Erythrocyte osmotic fragility test
The erythrocyte osmotic fragility (OF) test was performed as previously
described (Muro et al., 2000) from freshly drawn blood. Five WT C57BL/6
and FVB/NJ animals per gender and time point were analyzed. The
experiment was repeated three times with similar values. Results are
expressed as percentage of lysis in graded salt concentrations (mean±s.d. of
five males and five females). C50 values were determined by logarithmic
linearization of the OF curve.
Rotarod analysis
The coordination and balance ability on a rotating cylinder was assessed at
1 and 2 months of age with an accelerating apparatus as previously
described (Bortolussi et al., 2012).

















Brains were removed from the skulls and divided into two hemispheres: one
was subjected to brain histology, whereas the other was subjected to protein
extraction.
Brains from each genotype were fixed with 4% PFA in PBS overnight at
4°C. After cryoprotection in 20% sucrose, 0.02% sodium azide in PBS,
specimens were frozen in cryostat embedding medium (Bio-optica) and 14-
μm sagittal sections were obtained in a cryostat. Nissl staining was
performed as previously described (Bortolussi et al., 2012). For
immunofluorescence, 14-μm sagittal sections were blocked for 2 hours at
room temperature (RT) with 2.5% BSA in PBS 0.3% Triton X-100. After
blocking, specimens were incubated with the primary antibody for 2 hours
at RT in blocking solution with anti-calbindin (Synaptic Systems,
Goettingen, Germany). After 3×5-minute washes with blocking solution,
specimens were incubated with secondary antibody (Alexa Fluor 488;
Invitrogen Carlsbad, CA) for 2 hours at RT. Nuclei were visualized by
addition of Hoechst (10 μg/ml, Invitrogen) for 5 minutes after secondary
antibody solution.
TUNEL assay was performed using the In Situ Cell Death Detection Kit,
POD according to manufacturer’s instructions (Roche). Methyl green was
used as counterstaining.
Nissl-stained and TUNEL slides were mounted in Eukitt (Fluka, St Louis,
MO), whereas immunostained slides were mounted in Mowiol 4-88 (Sigma-
Aldrich).
Images were acquired on a Nikon Eclipse E-800 epifluorescent
microscope with a charge-coupled device camera (DMX 1200F; Nikon
Amstelveen, The Netherlands). Digital images were collected using ACT-1
(Nikon) software.
Analysis of the layer thickness was performed on Nissl-stained sections
by measuring the layer depth (μm) as previously described (Bortolussi et
al., 2012). PC number was calculated by counting calbindin-positive cells
in vermis sections along the entire cerebellum perimeter and expressed as
linear density (cell/mm) as previously described (Bortolussi et al., 2012).
Golgi staining was performed as described by Ranjan and Mallick
(Ranjan and Mallick, 2010) with minor modifications to adapt the method
to stain PCs of 15-day-old mice. Brains (n=4 mice for each group) were
divided into the two hemispheres along the midline and, after a wash in
PBS, they were submerged in the Golgi solution containing 5% of potassium
dichromate, 5% of mercuric chloride and 5% of potassium chromate.
Specimens were kept in darkness for 72 hours at 37°C. Golgi solution was
replaced every day to increase the staining. Later, brains were washed in
distillated water and sliced in a vibratome (Campden Instruments, MA752
motorised advance vibroslice) in 200-μm sagittal sections. Sections were
then treated according to the Ranjan and Mallick protocol, dehydrated and
mounted in Eukitt.
Ten PCs for each genotype/treatment were analyzed and a series of stack
images were collected at 40× magnification. Stacks were flattened with
ImageJ software to allow the quantification of specific parameters. Total
dendritic length, number of branches, average of dendrite length and Sholl
analysis were quantified using NeuroStudio software (Icahn School of
Medicine at Mount Sinai, NY). Sholl analysis was performed with
concentric circles of 10 μm. The complexity of the dentritic arbor is directly
related to the number of times the dendrites cross the concentric circles
(Sholl, 1953).
For spine density, ten segments of 50-μm long apical dendrites were
analyzed for each animal (four animals/treatment) as previously described
(Baj et al., 2014).
The genotype of the animals and the treatment were unknown to the
operator. A second operator analyzed the data. Measurements were averaged
for each animal. The results are expressed as mean±s.d. for each genotype.
Preparation of total protein extracts and western blot analysis
Cerebella were dissected and homogenized in RIPA buffer (150 mM NaCl,
1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris HCl pH 8, 2× protease
inhibitors) and analyzed by western blot analysis as described previously
(Bortolussi et al., 2012). Primary antibodies used were as follows: anti-
calbindin (Synaptic Systems, Goettingen, Germany) and anti-β-tubulin mAb
E7 (Developmental Studies Hybridoma Bank, Iowa City, IA).
Statistics
Results are expressed as mean±s.d. The Prism package (GraphPad Software,
La Jolla, CA) was used to analyze the data. Values of P≤0.05 were
considered statistically significant. Depending on the experimental design,
we used Student’s t-test, one-way ANOVA or two-way ANOVA, with
Bonferroni’s post-hoc comparison tests, as indicated in the legends to the
figures and text.
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Supplementary Fig. 1. Western blot analysis of total cerebellum protein extracts using an anti-calbindin1 anti-
body in P15 WT and PT-treated mutant mice. Tubulin was used as a loading control. Lower panel: densitometric quanti-
fication of the bands. ML, molecular layer; IGL, internal granular layer.
Movie 1. Untreated FVB/NJ-Ugt1-/- at P12 showing features of bilirubin encephalopathy such as lethargy, dystonia 
and seizures.
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   Ugt1	  allele	  
Genetic	  Background	   Post	  natal	  day	   WT	   MUT	  
C57Bl/6	   P2	   0.2	  ±	  0.1	  (8)	   11.8	  ±	  2.2	  (6)	  
	   P5	   0.2	  ±	  0.1	  (9)	   12.9	  ±	  1.7	  (10)	  
FVB/NJ	   P2	   0.3	  ±	  0.09	  (5)	   8.8	  ±	  0.9	  (3)	  
	   P5	   0.2	  ±	  0.02	  (4)	   10.4	  ±	  0.5	  (8)	  
	   P8	   0.2	  ±	  0.08	  (7)	   12.5	  ±	  0.9	  (8)	  
	   P10	   0.2	  ±	  0.1	  (5)	   14.4	  ±	  0.8	  (3)	  
	  
Supplementary	  Table	  1.	  Total	  plasma	  bilirubin	  levels	  in	  C57Bl/6	  &	  FVB/NJ	  
mice.	   Values	   represent	   means±SD.	   Values	   in	   parenthesis	   indicate	   number	   of	  
samples	  analysed.	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